A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
Study sponsor: Avalo Therapeutics, Inc. · AVTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-11Actual
Enrollment · participants91Actual
Source updated2024-09-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.